secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIOCRYST PHARMACEUTICALS INC (BCRX)
CIK:        0000882796
Form:       8-K
Filed at:   2025-05-05T23:59:59+00:00
Accession:  0001171843-25-002739
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioCryst Q1 ORLADEYO revenue $134.2M (+51% YoY); raises FY guidance to $580-600M; expects FY 2025 profitability
--------------------------------------------------------------------------------

- Q1 ORLADEYO net rev $134.2M (+51% YoY); total rev $145.5M (+56.8% YoY); net income $32K vs loss $35.4M.
- FY 2025 ORLADEYO rev guidance raised to $580-600M (from $535-550M); company expects net income and positive cash flow for full year.
- Paid down $75M of Pharmakon debt in April; expects ~$23.5M interest savings over life of loan.
- NDA submitted for ORLADEYO oral granules for HAE children aged 2-11; IND cleared for BCX17725 for Netherton syndrome.
- % paid ORLADEYO patients increased to ~84% (from 73.5% end 2024); U.S. preference for oral prophylaxis rose to 70%.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/882796/000117184325002739/0001171843-25-002739-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/882796/000117184325002739/f8k_050525.htm
  HTML page:      https://secwatch.observer/filing/0001171843-25-002739

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer